Five Alarm Bios raises £500k for anti-ageing treatments
Drug discovery company Five Alarm Bio has completed a seed investment round of more than £500,000 as it continues to explore anti-ageing treatments.
The Cambridge-based firm is looking to boost humanity’s resistance to age-related conditions, including arthritis, sarcopenia, and Alzheimer’s disease, among others.
The company will use the new funding to continue developing its cell lifespan extension therapies.
“Whilst life expectancy has increased over recent years, our healthy lifespan has not kept up. Anti-ageing science, therefore, has huge value,” said Five Alarm Bio CEO, Dr Janette Thomas.
“Here at FAB, our proprietary approach aims to overcome this fundamental challenge to human health as we work to discover and develop new drugs for age-associated diseases.”
The investment round included backing from Cambridge Angels, Meltwind, o2h Ventures, and SyndicateRoom, along with support from KPMG Acceleris.
“FAB is at the forefront of the rapidly growing anti-ageing therapeutics industry, with the potential to deliver new drugs that extend our healthy lifespan,” said Sunil Shah from o2h Ventures.
“The combination of the scientific depth of our CSO, William Bains, alongside the practical execution skills of the CEO, Janette Thomas, provides a great team to discover and develop new drugs for age-associated diseases.”
The seed funding follows a £360,000 Biomedical Catalyst grant from Innovate UK, given to the company in February last year.